Cargando…

Superimmunity by pan-sarbecovirus nanobodies

Vaccine boosters and infection can facilitate the development of SARS-CoV-2 antibodies with improved potency and breadth. Here, we observe superimmunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain (RBD). We rapidly isolate a large repertoire of specific ultra-high-...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Yufei, Huang, Wei, Liu, Hejun, Sang, Zhe, Nambulli, Sham, Tubiana, Jérôme, Williams, Kevin L., Duprex, W. Paul, Schneidman-Duhovny, Dina, Wilson, Ian A., Taylor, Derek J., Shi, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174178/
https://www.ncbi.nlm.nih.gov/pubmed/35738279
http://dx.doi.org/10.1016/j.celrep.2022.111004
_version_ 1784722183294025728
author Xiang, Yufei
Huang, Wei
Liu, Hejun
Sang, Zhe
Nambulli, Sham
Tubiana, Jérôme
Williams, Kevin L.
Duprex, W. Paul
Schneidman-Duhovny, Dina
Wilson, Ian A.
Taylor, Derek J.
Shi, Yi
author_facet Xiang, Yufei
Huang, Wei
Liu, Hejun
Sang, Zhe
Nambulli, Sham
Tubiana, Jérôme
Williams, Kevin L.
Duprex, W. Paul
Schneidman-Duhovny, Dina
Wilson, Ian A.
Taylor, Derek J.
Shi, Yi
author_sort Xiang, Yufei
collection PubMed
description Vaccine boosters and infection can facilitate the development of SARS-CoV-2 antibodies with improved potency and breadth. Here, we observe superimmunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain (RBD). We rapidly isolate a large repertoire of specific ultra-high-affinity nanobodies that bind strongly to all known sarbecovirus clades using integrative proteomics. These pan-sarbecovirus nanobodies (psNbs) are highly effective against SARS-CoV and SARS-CoV-2 variants, including Omicron, with the best median neutralization potency at single-digit nanograms per milliliter. A highly potent, inhalable, and bispecific psNb (PiN-31) is also developed. Structural determinations of 13 psNbs with the SARS-CoV-2 spike or RBD reveal five epitope classes, providing insights into the mechanisms and evolution of their broad activities. The highly evolved psNbs target small, flat, and flexible epitopes that contain over 75% of conserved RBD surface residues. Their potencies are strongly and negatively correlated with the distance of the epitopes from the receptor binding sites.
format Online
Article
Text
id pubmed-9174178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s).
record_format MEDLINE/PubMed
spelling pubmed-91741782022-06-08 Superimmunity by pan-sarbecovirus nanobodies Xiang, Yufei Huang, Wei Liu, Hejun Sang, Zhe Nambulli, Sham Tubiana, Jérôme Williams, Kevin L. Duprex, W. Paul Schneidman-Duhovny, Dina Wilson, Ian A. Taylor, Derek J. Shi, Yi Cell Rep Article Vaccine boosters and infection can facilitate the development of SARS-CoV-2 antibodies with improved potency and breadth. Here, we observe superimmunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain (RBD). We rapidly isolate a large repertoire of specific ultra-high-affinity nanobodies that bind strongly to all known sarbecovirus clades using integrative proteomics. These pan-sarbecovirus nanobodies (psNbs) are highly effective against SARS-CoV and SARS-CoV-2 variants, including Omicron, with the best median neutralization potency at single-digit nanograms per milliliter. A highly potent, inhalable, and bispecific psNb (PiN-31) is also developed. Structural determinations of 13 psNbs with the SARS-CoV-2 spike or RBD reveal five epitope classes, providing insights into the mechanisms and evolution of their broad activities. The highly evolved psNbs target small, flat, and flexible epitopes that contain over 75% of conserved RBD surface residues. Their potencies are strongly and negatively correlated with the distance of the epitopes from the receptor binding sites. The Author(s). 2022-06-28 2022-06-08 /pmc/articles/PMC9174178/ /pubmed/35738279 http://dx.doi.org/10.1016/j.celrep.2022.111004 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Xiang, Yufei
Huang, Wei
Liu, Hejun
Sang, Zhe
Nambulli, Sham
Tubiana, Jérôme
Williams, Kevin L.
Duprex, W. Paul
Schneidman-Duhovny, Dina
Wilson, Ian A.
Taylor, Derek J.
Shi, Yi
Superimmunity by pan-sarbecovirus nanobodies
title Superimmunity by pan-sarbecovirus nanobodies
title_full Superimmunity by pan-sarbecovirus nanobodies
title_fullStr Superimmunity by pan-sarbecovirus nanobodies
title_full_unstemmed Superimmunity by pan-sarbecovirus nanobodies
title_short Superimmunity by pan-sarbecovirus nanobodies
title_sort superimmunity by pan-sarbecovirus nanobodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174178/
https://www.ncbi.nlm.nih.gov/pubmed/35738279
http://dx.doi.org/10.1016/j.celrep.2022.111004
work_keys_str_mv AT xiangyufei superimmunitybypansarbecovirusnanobodies
AT huangwei superimmunitybypansarbecovirusnanobodies
AT liuhejun superimmunitybypansarbecovirusnanobodies
AT sangzhe superimmunitybypansarbecovirusnanobodies
AT nambullisham superimmunitybypansarbecovirusnanobodies
AT tubianajerome superimmunitybypansarbecovirusnanobodies
AT williamskevinl superimmunitybypansarbecovirusnanobodies
AT duprexwpaul superimmunitybypansarbecovirusnanobodies
AT schneidmanduhovnydina superimmunitybypansarbecovirusnanobodies
AT wilsoniana superimmunitybypansarbecovirusnanobodies
AT taylorderekj superimmunitybypansarbecovirusnanobodies
AT shiyi superimmunitybypansarbecovirusnanobodies